UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2019 January 8, 2019 (Original Report); January 8, 2019 (Amended Report)

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact name of Registrant as specified in its charter)

0-26224 51-0317849 Delaware (State or other jurisdiction of incorporation (Commission File Number) (I.R.S. Employer Identification or organization) No.)

> 311 Enterprise Drive Plainsboro, NJ 08536 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 8, 2019, Integra LifeSciences Holdings Corporation (the "Company") filed a Current Report on Form 8-K (the "Original Form 8-K") reporting the issuance of a press release announcing unaudited, preliminary fourth quarter 2018 financial results on revenues, organic revenues and adjusted earnings per share (the "Press Release"). This Amendment No. 1 on Form 8-K/A amends the Original Form 8-K to correct a typographical error contained therein regarding the content of the Press Release. As amended, this Amendment No. 1 correctly indicates that the Press Release announced the unaudited, preliminary fourth quarter 2018 financial results on revenues.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: January 8, 2019

By: <u>/s/ Glenn G. Coleman</u>

Glenn G. Coleman

Title: Corporate Vice President and Chief Financial Officer